Clinical Trial Update: Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating donor-derived CD19 CAR-T cells for relapsed/refractory B-cell acute lymphoblastic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Donor-Derived CD19 CAR-T Cells (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Zhejiang University | Conditions: B-cell Acute Lymphoblastic Leukemia | EARLY_Phase 1 | Status: RECRUITING